Adding venetoclax to hypomethylating agents increased composite remission but did not improve overall survival in HR-MDS.

Early low-dose lenalidomide significantly reduces mutational burden without increasing AML risk in non-transfusion-dependent del(5q) MDS.

Myelodysplastic syndromes (MDS) are cancers that make too few working blood cells, which can cause weakness, shortness of breath, bruising, and frequent infections. A balanced, high-energy eating plan ...

Bart Scott, MD, MS: Many patients wonder about what the complications are of transfusions. Transfusions, for the most part, are tolerated well, but they are not without [adverse] effects. We can take ...

NEET MDS 2026 result is expected today, June 2, with NBEMS likely to release the merit list, ranks and marks. Candidates can ...

Hypomethylating agents are standard in MDS treatment, with new drugs like Rytelo enhancing anemia management. Targeted therapies for IDH1/IDH2 mutations offer promising options, though challenges in ...

Myelodysplastic syndromes (MDS) are a group of blood cancers that affect the bone marrow and can result in a low levels of blood cells. When MDS affects red blood cells, it can lead to anemia in some ...

NEET MDS Result 2026 is likely to be released today. Candidates will be able to check the NEET MDS merit list and result PDFs on the official websites.